Phoenix Nest Inc.
NY
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 710 6th Ave #2a, Brooklyn, NY 11215, USA
- Website
- phoenixnestbiotech.com
- Founded
- 2012
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Kinea Bio Inc. | Mukilteo, WA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Modulo Bio, Inc. | San Diego, CA | — |
| Tega Therapeutics Inc. | San Diego, CA | 622110 General Medical and Surgical Hospitals |
| Infixion Bioscience Inc. | Escondido, CA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Research Vector | Philadelphia, PA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Phoenix Nest Inc., a woman-owned small business based in Brooklyn, New York, develops gene therapy manufacturing and analytical methods for rare neurological disorders as a recipient of federal research grants from the National Institute of Neurological Disorders and Stroke (NINDS). The vendor operates exclusively as a prime grant recipient; it holds no federal contracts, subcontracts, or IDV seats. Phoenix Nest's federal footprint consists entirely of NIH grants focused on Mucopolysaccharidosis Type IIIC (MPS IIIC or Sanfilippo Disease Type C), a fatal lysosomal storage disease with no existing treatment options.
Phoenix Nest's three recent grants span manufacturing scale-up, biomarker identification, and gene therapy development work under CFDA 93.853 (Extramural Research Programs in the Neurosciences and Neurological Disorders). The vendor is the recipient of a $1,492,329 grant awarded July 14, 2026, to manufacture and develop analytical methods for the JLK-247 gene therapy vector—a 500-liter cGMP lot to support a Phase I clinical trial treating MPS IIIC patients. The award requires manufacturing work to meet critical quality attributes of purity, potency, and sterility for clinical dosing, with performance in Brooklyn and ultimate completion by June 30, 2028. An earlier $1.4 million grant awarded July 1, 2024, funds identification of potential biomarkers and clinical tools for MPS IIIC patients, also concluding June 30, 2028. A third grant from September 19, 2022, funded development of the JLK-247 gene replacement therapy product, including tissue-level assessments in disease models, manufacturing scale-up, and GLP-regulated safety studies in animals to support IND filing.
All ten awards in the source data flow from HHS/NIH entities, with the National Institute of Neurological Disorders and Stroke accounting for seven awards. Two NINDS grants reach ultimate completion within the next twenty-four months and face recompete. The vendor's combined obligated funding across all awards totals $29.5 million, concentrated on a single therapeutic indication and a single federal customer pipeline.
Quick answers
Is Phoenix Nest Inc. registered in SAM.gov?
Yes. Phoenix Nest Inc.'s SAM.gov registration is active through August 5, 2027.
What is Phoenix Nest Inc.'s CAGE code?
Phoenix Nest Inc.'s CAGE code is 6PP02, and its Unique Entity ID (UEI) is C43HHASBLCV6.
What is Phoenix Nest Inc.'s most recent federal award?
Phoenix Nest Inc.'s most recent federal grant award is Manufacturing and analytical development for JLK-247 gene therapy (R44NS147802), from National Institute of Neurological Disorders and Stroke (NIH), on July 14, 2026.
On GovTribe
See Phoenix Nest Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors